{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:28:14Z","timestamp":1780363694476,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,1,25]],"date-time":"2014-01-25T00:00:00Z","timestamp":1390608000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1745-6215-15-37","type":"journal-article","created":{"date-parts":[[2014,1,25]],"date-time":"2014-01-25T10:01:12Z","timestamp":1390644072000},"source":"Crossref","is-referenced-by-count":16,"title":["Fluoxetine in Progressive Multiple Sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"15","author":[{"given":"Melissa","family":"Cambron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jop","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Haentjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"D\u2019Hooghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Nagels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Willekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothea","family":"Heersema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Debruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Van Hecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Algoed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"De Klippel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwin","family":"Fosselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laureys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Merckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Van Wijmeersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludo","family":"Vanopdenbosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Verhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Hupperts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Hengstman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Michiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Van Merhaegen-Wieleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"De Keyser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,25]]},"reference":[{"key":"1948_CR1","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrn3275","volume":"13","author":"PK Stys","year":"2012","unstructured":"Stys PK, Zamponi GW, van Minnen J, Geurts JJ: Will the real multiple sclerosis please stand up?. Nat Rev Neurosci. 2012, 13: 507-514. 10.1038\/nrn3275.","journal-title":"Nat Rev Neurosci"},{"key":"1948_CR2","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1093\/brain\/awq076","volume":"133","author":"E Leray","year":"2010","unstructured":"Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J, Edan G: Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010, 133: 1900-1913. 10.1093\/brain\/awq076.","journal-title":"Brain"},{"key":"1948_CR3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jns.2007.01.067","volume":"255","author":"M Koch","year":"2007","unstructured":"Koch M, Mostert J, Heersema D, De Keyser J: Progression in multiple sclerosis: further evidence of an age dependent process. J Neurol Sci. 2007, 255: 35-41. 10.1016\/j.jns.2007.01.067.","journal-title":"J Neurol Sci"},{"key":"1948_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/brain\/awl007","volume":"129","author":"C Confavreux","year":"2006","unstructured":"Confavreux C, Vukusic S: Natural history of multiple sclerosis: a unifying concept. Brain. 2006, 129: 606-616. 10.1093\/brain\/awl007.","journal-title":"Brain"},{"key":"1948_CR5","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1212\/01.WNL.0000146958.77317.3E","volume":"63","author":"H Panitch","year":"2004","unstructured":"Panitch H, Miller A, Paty D, Weinshenker B: Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004, 63: 1788-1795.","journal-title":"Neurology"},{"key":"1948_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/ana.21079","volume":"61","author":"JS Wolinsky","year":"2007","unstructured":"Wolinsky JS, Narayana PA, O'Connor P, Coyle PK, Ford C, Johnson K, Miller A, Pardo L, Kadosh S, Ladkani D: Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007, 61: 14-24. 10.1002\/ana.21079.","journal-title":"Ann Neurol"},{"key":"1948_CR7","first-page":"CD006643","volume":"1","author":"JI Rojas","year":"2010","unstructured":"Rojas JI, Romano M, Ciapponi A, Patrucco L, Cristiano E: Interferon Beta for primary progressive multiple sclerosis. Cochrane Database Syst Rev. 2010 Jan, 1: CD006643-","journal-title":"Cochrane Database Syst Rev"},{"key":"1948_CR8","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1212\/WNL.53.8.1628","volume":"53","author":"J De Keyser","year":"1999","unstructured":"De Keyser J, Wilczak N, Leta R, Streetland C: Astrocytes in multiple sclerosis lack beta-2 adrenergic receptors. Neurology. 1999, 53: 1628-1633. 10.1212\/WNL.53.8.1628.","journal-title":"Neurology"},{"key":"1948_CR9","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1073\/pnas.85.4.1292","volume":"85","author":"EM Frohman","year":"1988","unstructured":"Frohman EM, Vayuvegula B, Gupta S, van den Noort S: Norepinephrine inhibits gamma-interferon-induced major histocompatibility class II (Ia) antigen expression on cultured astrocytes via beta-2-adrenergic signal transduction mechanisms. Proc Natl Acad Sci U S A. 1988, 85: 1292-1296. 10.1073\/pnas.85.4.1292.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1948_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1001\/archneur.60.1.132","volume":"60","author":"J De Keyser","year":"2003","unstructured":"De Keyser J, Zeinstra E, Frohman E: Are astrocytes central players in the pathophysiology of multiple sclerosis?. Arch Neurol. 2003, 60: 132-136. 10.1001\/archneur.60.1.132.","journal-title":"Arch Neurol"},{"key":"1948_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.nbd.2003.10.012","volume":"15","author":"J De Keyser","year":"2004","unstructured":"De Keyser J, Zeinstra E, Wilczak N: Astrocytic beta2-adrenergic receptors and multiple sclerosis. Neurobiol Dis. 2004, 15: 331-339. 10.1016\/j.nbd.2003.10.012.","journal-title":"Neurobiol Dis"},{"key":"1948_CR12","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.pnpbp.2008.06.001","volume":"32","author":"AC Tramontina","year":"2008","unstructured":"Tramontina AC, Tramontina F, Bobermin LD, Zanotto C, Souza DF, Leite MC, Nardin P, Gottfried C, Goncalves CA: Secretion of S100B, an astrocyte-derived neurotrophic protein, is stimulated by fluoxetine via a mechanism independent of serotonin. Prog Neuropsychopharmacol Biol Psychiatry. 2008, 32: 1580-1583. 10.1016\/j.pnpbp.2008.06.001.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1948_CR13","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1136\/jnnp.2007.139345","volume":"79","author":"JP Mostert","year":"2008","unstructured":"Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, van Buchem MA, De Keyser J: Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry. 2008, 79: 1027-1031. 10.1136\/jnnp.2007.139345.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1948_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/S1474-4422(09)70043-2","volume":"8","author":"BD Trapp","year":"2009","unstructured":"Trapp BD, Stys PK: Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 2009, 8: 280-291. 10.1016\/S1474-4422(09)70043-2.","journal-title":"Lancet Neurol"},{"key":"1948_CR15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/jcbfm.2011.193","volume":"32","author":"M Cambron","year":"2012","unstructured":"Cambron M, D'Haeseleer M, Laureys G, Clinckers R, Debruyne J, De Keyser J: White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis. J Cereb Blood Flow Metab. 2012, 32: 413-424. 10.1038\/jcbfm.2011.193.","journal-title":"J Cereb Blood Flow Metab"},{"key":"1948_CR16","doi-asserted-by":"publisher","first-page":"5654","DOI":"10.1073\/pnas.1222560110","volume":"110","author":"M D\u2019Haeseleer","year":"2013","unstructured":"D\u2019Haeseleer M, Beelen R, Fierens Y, Cambron M, Vanbinst AM, Verborgh C, Demey J, De Keyser J: Cerebral hypoperfusion in multiple sclerosis is reversible and mediated by endothelin-1. Proc Natl Acad Sci U S A. 2013, 110: 5654-5658. 10.1073\/pnas.1222560110.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1948_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1023\/A:1014862808126","volume":"27","author":"EK Kong","year":"2002","unstructured":"Kong EK, Peng L, Chen Y, Yu AC, Hertz L: Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. Neurochem Res. 2002, 27: 113-120. 10.1023\/A:1014862808126.","journal-title":"Neurochem Res"},{"key":"1948_CR18","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00213-011-2190-y","volume":"216","author":"I Allaman","year":"2011","unstructured":"Allaman I, Fiumelli H, Magistretti PJ, Martin JL: Fluoxetine regulates the expression of neurotrophic\/growth factors and glucose metabolism in astrocytes. Psychopharmacology. 2011, 216: 75-84. 10.1007\/s00213-011-2190-y.","journal-title":"Psychopharmacology"},{"key":"1948_CR19","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1097\/00005344-200006000-00004","volume":"35","author":"Z Ungvari","year":"2000","unstructured":"Ungvari Z, Pacher P, Koller A: Serotonin reuptake inhibitor fluoxetine decreases arteriolar myogenic tone by reducing smooth muscle [Ca2+]i. J Cardiovasc Pharmacol. 2000, 35: 849-854. 10.1097\/00005344-200006000-00004.","journal-title":"J Cardiovasc Pharmacol"},{"key":"1948_CR20","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.neulet.2006.03.042","volume":"402","author":"JP Mostert","year":"2006","unstructured":"Mostert JP, Sijens PE, Oudkerk M, De Keyser J: Fluoxetine increases cerebral white matter NAA\/Cr ratio in patients with multiple sclerosis. Neurosci Lett. 2006, 402: 22-24. 10.1016\/j.neulet.2006.03.042.","journal-title":"Neurosci Lett"},{"key":"1948_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O\u2019Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011, 69: 292-302. 10.1002\/ana.22366.","journal-title":"Ann Neurol"},{"key":"1948_CR22","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","volume":"33","author":"JF Kurtzke","year":"1983","unstructured":"Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983, 33: 1444-1452. 10.1212\/WNL.33.11.1444.","journal-title":"Neurology"},{"key":"1948_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1177\/1352458509102626","volume":"15","author":"LV Bosma","year":"2009","unstructured":"Bosma LV, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman CH, Thompson AJ, Tintore M, Uitdehaag BM: The search for responsive clinical endpoints in primary progressive multiple sclerosis. Mult Scler. 2009, 15: 715-720. 10.1177\/1352458509102626.","journal-title":"Mult Scler"},{"key":"1948_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1527-3458.2008.00040.x","volume":"14","author":"JP Mostert","year":"2008","unstructured":"Mostert JP, Koch MW, Heerings M, Heersema DJ, De Keyser J: Therapeutic potential of fluoxetine in neurological disorders. CNS Neurosci Ther. 2008, 14: 153-164. 10.1111\/j.1527-3458.2008.00040.x.","journal-title":"CNS Neurosci Ther"},{"key":"1948_CR25","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1176\/jnp.5.3.322","volume":"5","author":"CN Karson","year":"1993","unstructured":"Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA: Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci. 1993, 5: 322-329.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1948_CR26","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1177\/1352458510370464","volume":"16","author":"LV Bosma","year":"2010","unstructured":"Bosma LV, Kragt JJ, Brieva L, Khaleeli Z, Montalban X, Polman CH, Thompson AJ, Tintore M, Uitdehaag BM: Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components?. Mult Scler. 2010, 16: 862-867. 10.1177\/1352458510370464.","journal-title":"Mult Scler"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-15-37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1745-6215-15-37\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-15-37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T03:11:07Z","timestamp":1548213067000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/1745-6215-15-37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,25]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1948"],"URL":"https:\/\/doi.org\/10.1186\/1745-6215-15-37","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,25]]},"article-number":"37"}}